Abstract
Background: We describe the case of an 11-year-old boy affected by chronic granulomatous disease complicated by a Crohn’s like colitis needing prolonged treatment with oral corticosteroids.
Case Presentation: His therapy for the control of severe oral mucositis was based on topical clobetasol, which did not decrease once the steroids were discontinued. Two years after the oral interruption of the steroids, cushingoid characteristics persisted, the cause of which, after a thorough investigation, was found to be the persistence of the topical clobetasol oral gel.
Conclusion: Several studies investigated the efficacy of topical clobetasol for immuno-related mucositis, but little is known about its pharmacokinetics and side effects. In this report, we have reviewed the literature, defining a maximum putative dose of clobetasol mucosal gel to avoid Cushing syndrome.
Keywords: clobetasol, iatrogenic, cushingoid, adrenal suppression, cushingoid syndrome, mucositis, case report.
Graphical Abstract
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Topical Clobetasol: An Overlooked Cause of Cushing Syndrome
Volume: 21 Issue: 12
Author(s): Sergio Ghirardo, Laura De Nardi, Alberto Tommasini, Egidio Barbi and Gianluca Tornese*
Affiliation:
- Institute for maternal and child health IRCCS ‘Burlo Garofolo’, Trieste,Italy
Keywords: clobetasol, iatrogenic, cushingoid, adrenal suppression, cushingoid syndrome, mucositis, case report.
Abstract:
Background: We describe the case of an 11-year-old boy affected by chronic granulomatous disease complicated by a Crohn’s like colitis needing prolonged treatment with oral corticosteroids.
Case Presentation: His therapy for the control of severe oral mucositis was based on topical clobetasol, which did not decrease once the steroids were discontinued. Two years after the oral interruption of the steroids, cushingoid characteristics persisted, the cause of which, after a thorough investigation, was found to be the persistence of the topical clobetasol oral gel.
Conclusion: Several studies investigated the efficacy of topical clobetasol for immuno-related mucositis, but little is known about its pharmacokinetics and side effects. In this report, we have reviewed the literature, defining a maximum putative dose of clobetasol mucosal gel to avoid Cushing syndrome.
Export Options
About this article
Cite this article as:
Ghirardo Sergio , De Nardi Laura , Tommasini Alberto , Barbi Egidio and Tornese Gianluca *, Topical Clobetasol: An Overlooked Cause of Cushing Syndrome, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (12) . https://dx.doi.org/10.2174/1871530321666210426131423
DOI https://dx.doi.org/10.2174/1871530321666210426131423 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism
Current Hypertension Reviews The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond
Current Pharmaceutical Design Port-a-Patch and Patchliner: High Fidelity Electrophysiology for Secondary Screening and Safety Pharmacology
Combinatorial Chemistry & High Throughput Screening Correspondence Section
Current Drug Targets Cardiovascular Risk in Psoriasis: Current State of the Art
Current Vascular Pharmacology Editorial [Hot Topic: New Therapeutic Options in Central Nervous System Involvement of Rheumatologic Diseases (Executive Editor: Ali Gur)]
Current Pharmaceutical Design Organizational Impact of the Introduction of a New Portable Syringe Pump for Iloprost Therapy in Italian Hospital Settings
Current Drug Therapy Pioglitazone and Rosiglitazone: Effects of Treatment with a Thiazolidinedione on Lipids and Non Conventional Cardiovascular Risk Factors
Current Clinical Pharmacology Sonoelastography for Pelvic Metastatic Malignant Pheochromocytoma: A Case Report
Current Medical Imaging Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Renal Function Impairment in Patients Undergoing Elective EVAR vs. Elective Open Repair During Follow up Period: A Systematic Review of the Literature
Current Vascular Pharmacology Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry Bio-analytical Method Development and Validation of Tadalafil with a Special Emphasis on Pharmacokinetic Study in Healthy Indian Subjects for the ODS Formulation
Current Analytical Chemistry The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers